spacer
home > pmps > winter 2003 > new developments in the containment of pharmaceutical powders
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

New Developments in the Containment of Pharmaceutical Powders

There is a growing trend for routine day-to-day pharmaceutical powder processing and production operations to involve 'high potency' powders. To meet this challenge new strategies for powder handling are being developed along with engineering advances in the equipment used to contain the active or high potency materials. The term 'containment', of course, refers to the isolation of hazardous materials (high potency) using engineering methods in various guises. Containment can protect the operator from the compound or protect the compound from operator-borne containment. In some cases specialised containment devices protect the operator from the materials and vice versa.

First of all it is important to appreciate the growth of high potency compounds within the pharmaceutical industry. In 1990, only about five per cent of all pharmaceutical actives handled were considered potent. Now in the year 2001, over 30 per cent of all APIs are classified as 'potent', and therefore require special attention to protect the operator from the effects of coming into contact with these materials.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Martyn Ryder, Director of Extract Technology, part of the Carlisle Sciences Group

Martyn Ryder, Vice President of Business Development at Carlisle Life Sciences Europe, was educated at Leeds Polytechnic in HVAC and Building Services. In 1981 he founded Extract Technology, a company which has grown to be one of the world's leading suppliers of pharmaceutical dust control and high containment systems. The company is now part of the Carlisle Life Sciences Group, a division of Carlisle Corporation, a diversified global manufacturing company, serving the transportation, construction, commercial roofing, automotive, food service, data transmission and pharmaceutical and biotech industries.

spacer
Martyn Ryder
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease, pachyonychia congenita

MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study.
More info >>

White Papers

Preparation of Pharmaceutical Samples for Metals Analysis

RSSL

There has been a lot of discussion regarding the methods of analysis for pharmaceutical products as we await the upcoming changes to both the EP and USP, relating to the analysis of metal impurities.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement